4 transcripts
RVMD
Earnings call transcript
NASDAQ
2024 Q2
7 Aug 24
promising. The most common adverse events are believed to be on target and associated with the inhibition of wild-type RAS in normal tissue.
Most adverse
RVMD
Earnings call transcript
NASDAQ
2024 Q1
8 May 24
. Observation of complete responses in lung, pancreatic and melanoma patients signifies the potential power of targeting RAS addiction with this compound
RVMD
Earnings call transcript
NASDAQ
2023 Q4
26 Feb 24
clinical profiles of two unprecedented targeted RAS(ON) inhibitors, RMC-6236, a RAS(ON) multi-selective inhibitor and RMC-6291, a RAS(ON) G12C selective
RVMD
Earnings call transcript
NASDAQ
2023 Q2
8 Aug 23
announced our intention to present additional supporting clinical data on RMC-6236 at the AACR-NCI-EORTC International Conference on Molecular Targets
- Prev
- 1
- Next